Did You Lose Money on ADMA Biologics, Inc. (ADMA)?
A securities class action has been filed on behalf of investors who purchased or acquired ADMA Biologics, Inc. securities during the class period below and suffered a financial loss.
- Ticker / Exchange
- ADMA · NASDAQ
- Class Period
- August 8, 2023 – April 15, 2025
Lead Plaintiff Deadline
September 2, 2026
18 days remaining
- No cost or obligation to participate
- Attorneys work on a contingency-fee basis
- Confidential case review by experienced counsel
Company
ADMA Biologics, Inc.
Class Period
August 8, 2023 – April 15, 2025
Lead Plaintiff Deadline
September 2, 2026
Case Type
Securities Class Action
What Is the ADMA Lawsuit About?
A securities class action has been filed alleging that ADMA Biologics, Inc. and certain of its officers made materially false and misleading statements concerning the company's plasma supply, manufacturing yields and regulatory compliance. According to the complaint, defendants represented that production capacity and yield improvements were on track while allegedly concealing operational issues. When information regarding these issues allegedly reached the market, the price of ADMA securities declined, causing losses to investors who purchased during the class period.
These are allegations contained in the filed complaint. No court has made a final determination regarding the merits of the claims.
Key Allegations
- The complaint alleges undisclosed manufacturing and yield challenges.
- Plasma supply assumptions are alleged to have lacked a reasonable basis.
- Alleged deficiencies in internal controls over financial reporting.
- Investors allegedly suffered losses when the claimed truth emerged.
Who May Be Eligible?
You may be eligible if you purchased or acquired ADMA Biologics, Inc. securities during the class period and suffered a financial loss. The class period runs from August 8, 2023 to April 15, 2025.
- You purchased or acquired ADMA Biologics, Inc. securities during the class period.
- You suffered a financial loss in connection with those holdings.
- You do not necessarily need to serve as lead plaintiff to potentially participate in any future recovery. The lead plaintiff is a representative party who acts on behalf of other class members; class members may participate without taking on that role.
The lead plaintiff deadline is September 2, 2026.
Check My EligibilityWhat Happens Next
- 1
Submit Your Information
Complete the short form so the team can identify the case and your potential eligibility.
- 2
Eligibility and Transaction Review
Additional transaction records or brokerage statements may be requested to evaluate your submission.
- 3
The Legal Team May Contact You
If appropriate, a member of the team may reach out to discuss next steps regarding this matter.
Why Investors Contact Levi & Korsinsky
Securities Litigation Experience
Approved firm credential — supply approved copy describing the firm's securities litigation practice.
Verified Settlement History
Verified settlement figure — insert legally approved recovery figures from the CMS.
Secure and Confidential Review
Your submission is handled confidentially and used to evaluate this matter.
No Upfront Cost
Approved no-upfront-cost statement — display only if approved by the legal team.
Attorney advertising. Prior results do not guarantee a similar outcome. Statements marked as requiring approval are placeholders pending legal review.
Questions & answers
Frequently asked questions
Other Active Investigations
Investors in these companies may also be eligible to participate.